Metabolomics Market Driven by Growing R&D in Pharmaceuticals Sector

Published Date : Jun 07, 2016

Metabolomics is the study of the set of metabolites present in a cell and tissue of an organism. It is used to identify and quantify the cellular metabolites by making use of refined analytical technologies, with the help of statistical and multi-variant methods. According to a report published by a market intelligent company called Transparency Market Research (TMR), the global metabolomics market is projected to expand at a CAGR of 17.1% between 2016 and 2024 and reach US$2,494.8 mn by 2024.

Rising Demand for Personalized Medicines to Boost Metabolomics Market

The global metabolomics market is expected to witness a significant growth due to the rising demand for personalized medicines across North America and Europe especially. The growing research and development activities across pharmaceuticals and biotechnology sectors are expected to push the global metabolomics market. Furthermore, the combination of various academic research institutes with the leading players operating in the market is expected to drive the metabolomics market. On the other hand, the market is expected to be restrained by the reluctance to adopt advanced technology by traditional professionals. 

High Performance Liquid Chromatography (HPLC) Segment Accounts for Highest Share of Market

The global metabolomics market is segmented on the basis of technique into separation technique, detection technique. The separation technique includes the study of capillary electrophoresis, ultra-performance liquid chromatography (UPLC), gas chromatography, and high performance liquid chromatography (HPLC). Of these, the high performance liquid chromatography (HPLC) segment accounted for the largest share of the metabolomics market by technique. 

The metabolomics market is segmented on the basis of drug assessment, biomarker discoveries, nutrigenomics, clinical toxicology, and others. The market is dominated by the presence of leading players such as Thermo Fisher Scientific, Inc., Biocrates Life Sciences AG, Shimadzu Corporation, and Human Metabolome Technologies, Inc. among others.